Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1999 1
2000 5
2001 4
2002 2
2003 1
2004 5
2005 3
2006 1
2007 4
2009 1
2010 2
2011 1
2013 2
2014 2
2015 2
2016 1
2017 1
2019 4
2020 1
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies.
Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg JE, Hernandez-Molina G, Kocher A, Kostov B, Kruize AA, Mandl T, Ng WF, Retamozo S, Seror R, Shoenfeld Y, Sisó-Almirall A, Tzioufas AG, Vitali C, Bowman S, Mariette X; EULAR-Sjögren Syndrome Task Force Group. Ramos-Casals M, et al. Ann Rheum Dis. 2020 Jan;79(1):3-18. doi: 10.1136/annrheumdis-2019-216114. Epub 2019 Oct 31. Ann Rheum Dis. 2020. PMID: 31672775 Free article.
The therapeutic management of Sjogren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target beyond the relief of symptoms as the most important goal. ...The recomme …
The therapeutic management of Sjogren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain chal …
Treatment of xerostomia in Sjogren's syndrome - what effect does it have on the oral microbiome?
Muszyński D, Kucharski R, Marek-Trzonkowska N, Kalinowska M, Brzóska A, Bolcewicz M, Kalinowski L, Kaźmierczak-Siedlecka K. Muszyński D, et al. Front Cell Infect Microbiol. 2025 Apr 14;15:1484951. doi: 10.3389/fcimb.2025.1484951. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40297612 Free PMC article. Review.
Sjogren's syndrome is an autoimmune disease characterized by lymphatic infiltration of secretory tissues. The disease results in dryness of the eyeball or mouth, which often occur simultaneously. Agents used to treat Sjogren's syndrome may improve oral …
Sjogren's syndrome is an autoimmune disease characterized by lymphatic infiltration of secretory tissues. The disease results …
Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjogren's syndrome.
Noaiseh G, Baker JF, Vivino FB. Noaiseh G, et al. Clin Exp Rheumatol. 2014 Jul-Aug;32(4):575-7. Epub 2014 Jul 23. Clin Exp Rheumatol. 2014. PMID: 25065774
OBJECTIVES: There are currently no head-to-head comparisons of sialagogues for Primary Sjogren's syndrome (pSS). We compared the tolerability and side effect profile of pilocarpine and cevimeline in patients with pSS and determined clinical, laboratory …
OBJECTIVES: There are currently no head-to-head comparisons of sialagogues for Primary Sjogren's syndrome (pSS). We compared t …
Management Strategies for Xerostomia in Patients with Sjogren's Syndrome: A Comprehensive Review.
Swathi D, Sailo JL, Ausare SS, Bhattacharjee D, Buvariya S, Dolker T, Maini AP. Swathi D, et al. J Pharm Bioallied Sci. 2025 May;17(Suppl 1):S74-S76. doi: 10.4103/jpbs.jpbs_1451_24. Epub 2025 Feb 28. J Pharm Bioallied Sci. 2025. PMID: 40511233 Free PMC article. Review.
Xerostomia, commonly known as dry mouth, is a significant complication in patients with Sjogren's syndrome (SS), an autoimmune disorder primarily affecting the salivary glands. This comprehensive review discusses the various management strategies available to …
Xerostomia, commonly known as dry mouth, is a significant complication in patients with Sjogren's syndrome (SS), an aut …
Meta-analysis on pharmacological therapies in the management of xerostomia in patients with Sjogren's syndrome.
Garlapati K, Kammari A, Badam RK, B E S, Boringi M, Soni P. Garlapati K, et al. Immunopharmacol Immunotoxicol. 2019 Apr;41(2):312-318. doi: 10.1080/08923973.2019.1593448. Epub 2019 Apr 1. Immunopharmacol Immunotoxicol. 2019. PMID: 30932714
Introduction: Sjogren's syndrome is an immunologic disorder, characterized by symptoms of dry mouth and dry eyes. ...Hence, the present study is aimed at evaluation and comparison of different pharmacological agents in the management of xerostomia in patients …
Introduction: Sjogren's syndrome is an immunologic disorder, characterized by symptoms of dry mouth and dry eyes. ...Hence, th …
Pharmacotherapy of xerostomia in primary Sjogren's syndrome.
Wall GC, Magarity ML, Jundt JW. Wall GC, et al. Pharmacotherapy. 2002 May;22(5):621-9. doi: 10.1592/phco.22.8.621.33218. Pharmacotherapy. 2002. PMID: 12013361 Review.
We reviewed the current literature concerning the treatment of dry mouth in patients with primary Sjogren's syndrome (SJS). Computerized MEDLINE search engines were used with the terms Sjogren, xerostomia, dry mouth, and treatment. ...Pharmacotherapy i …
We reviewed the current literature concerning the treatment of dry mouth in patients with primary Sjogren's syndrome (SJS). Co …
Salivary enhancement therapies.
Fox PC. Fox PC. Caries Res. 2004 May-Jun;38(3):241-6. doi: 10.1159/000077761. Caries Res. 2004. PMID: 15153695 Review.
A large number of systemic agents have also been proposed as secretagogues, but only a few have shown consistent salivary enhancing properties in well-designed, controlled trials. Pilocarpine has been shown to improve symptoms of oral dryness and to increase salivary outpu …
A large number of systemic agents have also been proposed as secretagogues, but only a few have shown consistent salivary enhancing properti …
Xerostomia secondary to Sjogren's syndrome in the elderly: recognition and management.
Al-Hashimi I. Al-Hashimi I. Drugs Aging. 2005;22(11):887-99. doi: 10.2165/00002512-200522110-00001. Drugs Aging. 2005. PMID: 16323968 Review.
Xerostomia is a common symptom in the elderly population. Studies have suggested that the underlying cause of approximately 40% of xerostomia in the elderly is Sjogren's syndrome. ...Currently, the mechanism(s) of development and progression of Sjog …
Xerostomia is a common symptom in the elderly population. Studies have suggested that the underlying cause of approximately 40% of …
Update in Sjogren syndrome.
Fox RI, Stern M, Michelson P. Fox RI, et al. Curr Opin Rheumatol. 2000 Sep;12(5):391-8. doi: 10.1097/00002281-200009000-00007. Curr Opin Rheumatol. 2000. PMID: 10990175 Review.
Sjogren syndrome (SS), the second most common autoimmune rheumatic disease, refers to keratoconjunctivitis sicca and xerostomia resulting from immune lymphocytes that infiltrate the lacrimal and salivary glands. ...Orally administered agonists of the muscarinic M3 r …
Sjogren syndrome (SS), the second most common autoimmune rheumatic disease, refers to keratoconjunctivitis sicca and xerostomia …
The management of Sjogren's syndrome.
Mavragani CP, Moutsopoulos NM, Moutsopoulos HM. Mavragani CP, et al. Nat Clin Pract Rheumatol. 2006 May;2(5):252-61. doi: 10.1038/ncprheum0165. Nat Clin Pract Rheumatol. 2006. PMID: 16932698 Review.
Sjogren's syndrome is a chronic autoimmune disorder, characterized by lymphocytic infiltration and malfunction of the exocrine glands, resulting in dry mouth and eyes. The syndrome can present either alone (primary Sjogren's syndrome) or in the context …
Sjogren's syndrome is a chronic autoimmune disorder, characterized by lymphocytic infiltration and malfunction of the exocrine …
44 results